Everything tagged "healthcare" across the TickerSpark archives.
Intuitive Surgical trades at a premium because it is still delivering premium operating results. With procedure growth running around 17%, revenue up 20.5%, and the da Vinci installed base still expanding double digits, the usual "too expensive" knock misses what the business is actually doing.
Eli Lilly's next move looks less like a pipeline trade and more like an access trade. Demand was never the problem; broader PBM coverage and expected Medicare access starting July 1 make the revenue conversion story more immediate.
Healthcare’s leadership over tech and semis looks less like a defensive flinch and more like a valuation message from a still-hawkish market. With rates staying restrictive, investors are rewarding nearer-term earnings durability and demanding a higher bar for crowded long-duration growth.
A seven-stock healthcare countdown spans telehealth, devices, life-science tools, diagnostics, distribution, and managed care, with HIMS, BDX, TMO, DHR, and ABT in focus.
The short-report hit on Ensign is serious, but the selloff is running into a business that just posted record occupancy, 21.7% adjusted EPS growth, and higher full-year guidance. We see this as a test of whether allegations can overpower a long-running execution story, and right now execution still has the better numbers.
Medtronic finally has a growth story that looks big enough to matter at the company level, not just in a niche product line. With cardiac ablation surging and valuation still well below faster-loved device peers, MDT looks like the more compelling catch-up trade here.
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
Abivax just posted the kind of Phase 3 efficacy biotech investors wait years to see, and the stock still got cut nearly in half because the market fixated on a safety overhang. That risk is real, but a 44.1% one-day collapse looks more like panic repricing than a fair read on a drug that delivered 50%+ remission in maintenance.
Boston Scientific’s plunge looks like a real reset, not a bargain-bin overreaction. Management already cut 2026 growth guidance, then reinforced that Watchman weakness is tied to a worsening procedure mix that the market can’t just wave away.
Merck’s patent-cliff problem is real, but the market is acting like the runway ends tomorrow when the core franchise is still expanding today. Fresh lung-cancer data, rising Keytruda sales, and a packed oncology catalyst calendar make MRK look stronger than the fear trade suggests.
Health insurers are finally showing signs that the medical-cost spike is easing, but that is not the same thing as a clean, durable margin reset across the group. The better trade still looks selective: some operators are stabilizing, while others remain too expensive or too exposed to unresolved Medicare Advantage and Medicaid pressure.
Sonida Senior Living, Inc. (SNDA) slips 3.3% after reporting earnings misses, as investors react to weaker-than-expected results and pressure on the stock.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime